Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-beta kinase pathway. by Escotte, Sandie et al.
Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis
bronchial epithelial cells via IKK-b kinase pathway
S. Escotte*, O. Tabary*, D. Dusser#, C. Majer-Teboul}, E. Puchelle*, J. Jacquot*
Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial
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ABSTRACT: Inhaled fluticasone propionate (FP) is widely used to reduce pulmonary
inflammation in chronic obstructive pulmonary disease, but the potential effects of FP
on airway epithelial cells from patients with cystic fibrosis (CF) are unknown. In CF
disease, a nonregulated inflammatory lung response occurs through exaggerated
nuclear factor (NF)-kB activation and elevated pro-inflammatory cytokines production
by airway epithelial cells.
To determine whether FP reduces cytokine production in bronchial epithelial cells via
NF-kB, the authors investigated the nonstimulated and the Pseudomonas aeruginosa
lipopolysaccharide (LPS) stimulated production of NF-kB-dependent interleukin (IL)-
6, IL-8 and RANTES (regulated on activation, T-cell expressed and secreted) along
with the activation of NF-kB in non-CF and CF human bronchial gland epithelial cells.
It was demonstrated that a relevant concentration of FP (10-8 M) inhibited
constitutive and P. aeruginosa LPS-induced IL-6 and IL-8 production of non-CF and
CF bronchial epithelial cells. Interestingly, the expression of two IkB kinases (IKK)-
a/b, the degradation of cytosolic IkB-b inhibitor and the NF-kB deoxyribonucleic acid
binding activity were markedly reduced after FP treatment in both CF and non-CF
bronchial epithelial cells.
It was shown by the authors that fluticasone propionate exerts an anti-inflammatory
effect by blocking a signal transduction leading to a reduced level of IkB-a/b kinases
in bronchial epithelial cells. In particular the strong effect on the IkB-b kinase, which
is known to be elevated in bronchial epithelial cells in cystic fibrosis patients, was
observed.
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Cystic fibrosis (CF) is a lethal inherited disorder caused
by mutations in the gene encoding the CF transmembrane
conductance regulator (CFTR) in airway epithelial cells [1].
One of the major clinical manifestations of CFTR mutations
is neutrophil dominated inflammation [2, 3], implying that
defective CFTR affects the immune function of airway
epithelial cells, in particular the production of nuclear factor
(NF)-kB-dependent chemokines. Increasing evidence suggests
that respiratory epithelial cells with dysfunctional CFTR
have exaggerated activation of NF-kB/inhibitor of NF-kB
complex associated with upregulated expression of chemokines
[4, 5]. The present authors and previous studies, have previously
demonstrated that epithelial expression of interleukin (IL)-8
is excessively elevated in the bronchial epithelial cells of
human CF adults [6]. This was observed in both matched
CF and corrected respiratory epithelial cell lines [7, 8] and
in CF transmembrane conductance regulator homozygous
deficient mice (CFTR-/-) compared to normal mice after
Pseudomonas aeruginosa stimulation [9]. How CFTR dys-
function in CF airway cells contributes to the activation and
nuclear localisation of NF-kB is still unclear. Recently, an
in vitro study on the expression of DF508 CFTR (CFTR
which contains a deletion of phenylalanine at position 508) in
the ovary cells of Chinese hamsters, which do not express
CFTR, revealed a seven-fold increase in the activation of
NF-kB compared to the wild-type CFTR or the G551D
mutant. This effect was also paralleled with elevated IL-8
expression [5].
Therapeutic strategies include the blocking of transcrip-
tion factors such as NF-kB that lead to inflammatory gene
activation and the inhibition of signaling pathways that are
stimulated in lung diseases. The effects of corticosteroids are
predominantly mediated by the inhibition of NF-kB deoxy-
ribonucleic acid (DNA)-binding activity, which controls genes
encoding inflammatory cytokines, chemokines and adhesion
molecules in respiratory epithelial cells [10–13]. The inhaled
steroid fluticasone propionate (FP) is widely used clinically
as an anti-inflammatory and immunosuppressive agent, espe-
cially in the treatment of asthma [14] and allergic rhinitis
[15]. Recent reports suggest that in vivo administration of
FP attenuates pulmonary inflammation through its ability
to reduce the number of eosinophils in airway biopsies [16]
and inhibit neutrophil chemotaxis [17]. FP induces apoptosis
of eosinophils [18] and also reduces the production of
several cytokines such as IL-1b, IL-6, IL-8 and RANTES
(regulated on activation, T-cell expressed and secreted) by
alveolar macrophages [19] and lymphocytes [20, 21]. Despite
all of these anti-inflammatory effects, molecular targets of
FP in bronchial epithelial cells are unknown. Understan-
ding such mechanisms is of great interest and may lead to
the development of new therapeutic approaches capable of
reducing airway inflammation, which is early, excessive and
sustained in CF patients.
The aims of the present study were to: 1) evaluate the ability
of FP to reduce the constitutive and P. aeruginosa lipopoly-
saccharide (LPS)-induced production of pro-inflammatory
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cytokines IL-6, IL-8 and RANTES in cultured bronchial
gland epithelial cells from CF and non-CF patients; and




Cell isolation and culture procedures of human bronchial
submucosal gland epithelial cells were performed on bron-
chial tissues collected from adult CF patients (all DF508
homozygous for CFTR mutation) and non-CF control
patients undergoing lung transplantation, as previously described
[22]. Bronchial tissues for non-CF control experiments were
obtained from patients with primary pulmonary hyper-
tension and pulmonary idiopathic fibrosis. Bronchial gland
epithelial cells were isolated by enzymatic digestion from
bronchial submucosa and grown on type I, collagen coated,
25 cm2 tissue-culture flasks in Dulbecco modified Eagle9s
medium (DMEM) with Ham9s F12 (50/50%, v/v), supple-
mented with 1% Ultroser G (a serum substitute; Sepracor,
Villeneuve-la-Garenne, France), glucose (10 g?L-1), sodium
pyruvate (0.33 g?L-1). Penicillin G (100 U?mL-1) and strep-
tomycin (100 mg?mL-1) were also added as antibiotics.
Exposure of cystic fibrosis and noncystic fibrosis
bronchial epithelial cells to fluticasone propionate
CF and non-CF bronchial epithelial cells (16104 cells) were
grown in 24-well culture plates. Prior to their exposure to
FP, CF and non-CF bronchial epithelial cells were incubated
for 16 h in an Ultroser G-free DMEM/Ham9s F12 medium
in 95% air and 5% CO2. At the end of the 16-h period, CF
and non-CF bronchial epithelial cells were pretreated with
either DMEM/Ham9s F12 medium alone or the medium with
various concentrations of FP (10-9–10-6 M) for 2 h. After-
wards the cells were activated for 4 h with DMEM/Ham9s
F12 containing 1.0 mg?mL-1 P. aeruginosa LPS (serotype 10;
Calbiochem, San Diego, CA, USA). A stock solution of
FP (10-3 M) generously provided by GlaxoSmithKline was
prepared in 99.5% ethanol (Merck Eurolab, Darmstadt,
Germany). FP was further diluted with DMEM/Ham9s F12
medium to final FP concentrations (10-9–10-6 M) and used
throughout the experiments. Immediately after each period of
cell exposure, cells and culture supernatants were collected
and stored at -80uC.
Enzyme-linked immunoabsorbent assay for interleukin-6
and intereukin-8 and regulated on activation, T-cell
expressed and secreted
The enzyme-linked immunoabsorbent assay (ELISAs) for
IL-6, IL-8 and RANTES cytokine detection, were sensitive
at 2 pg?mL-1, 5 pg?mL-1 and 2 pg?mL-1 respectively, were
performed by following the manufacturer9s instructions
(Biosource International, Camarillo, CA, USA). All reagents
were molecular biology grade and all buffers and solutions
were prepared using pyrogen-free grade water. In all culture
supernatants, undetectable levels of endotoxin (detection limit
o5 pg?mL-1) were found using a quantitative chromogenic
Limulus Amoebocyte Lysate assay (LAL; Bio Whittaker,
Emerainville, France). Cell viability of CF and non-CF
bronchial epithelial cells always exceeded 97%, as determined
by trypan blue exclusion, after all experimental procedures.
Data were expressed either as ng?mL-1 per 106 viable cells
or as released cytokine percentage compared to control.
Immunofluorescence for IkB-a kinase expression
CF and non-CF bronchial epithelial cells cultured in
the absence or presence of FP (10-8 M, 16 h) were fixed
in situ in cold methanol at -20uC, air dried, and rehydrated in
phosphate-buffered saline (PBS) at pH 7.2. Cells were stained
for IkB-a expression using sheep antiserum to human IkB-a
(Serotec Ltd, Oxford, UK) for 1 h at room temperature
and a donkey anti-sheep fluorescein isothiocyanate (FITC)
conjugated antibody (Ab) for 45 min at room temperature
as previously described [23]. Negative controls were obtained
by using either nonspecific immunoglobulin (Ig)G as the
primary Ab (M7769; Sigma Aldrich Chimie, Lyon, France)
or FITC conjugated Ab alone. Representative fields of CF
and non-CF bronchial gland cells cultured in different
conditions were recorded using a Zeiss Axiophot microscope
(Zeiss, Le Pecq, France).
Cell extracts and Western blot analysis
CF and non-CF bronchial epithelial cells cultured in the
absence or presence of FP (10-8 M, 16 h) were washed in PBS
(pH 7.2) and cell proteins were extracted (15 min, 4uC) in
radioimmunoprecipitation buffer (50610-3 M Tris, pH 7.4,
15610-4 M NaCl, 1% Triton X100, 0.1% sodium doodecyl-
sulphate, 5610-3 M iodoacetamide, sodium deoxycholate
and 1% Nonidet P-40), which was supplemented with 1%
phenylmethylsulfonyl fluoride. Cells were then harvested and
the protein extracts were centrifuged (12,5006g, 10 min, 4uC).
Supernatants were collected and used to assay IkB-a inhibitor
and the two IkB kinases (IKK-a/b) as previously described
[22]. An equal amount of protein (10 mg?mL-1) from each
protein extraction was submitted to electrophoresis under
denaturing conditions using 4–15% polyacrylamide gels
(Pharmacia Biotech., Paris, France). The gels were then trans-
ferred onto a nitrocellulose membrane (Millipore, Bedford,
MA, USA) by electroblotting. After successive washes, the
membranes were analysed by using the Western blot techni-
que with rabbit polyclonal antihuman IkB-a, antihuman
IKK-a and antihuman IKK-b antibodies (Santa Cruz Bio-
technology, CA, USA) and developed with an enhanced
chemiluminescence kit (Amersham Life Science, Freiburg,
Germany). Densitometric analysis of Western blots was
performed on a Bio-Rad model GS-690 imaging densito-
meter. The gels were scanned in the transmittance mode at a
resolution setting of 800 dots per inch. The intensity of each
band was compared with the adjusted volume (mean optical
density6area in mm2).
Nuclear protein extraction and electrophoretic mobility
shift assay
Nuclear extracts were prepared and analysed after the
CF and non-CF bronchial epithelial cells were incubated
in different conditions, as previously described [22]. Nuclear
extracts of CF and non-CF bronchial epithelial cells were incu-
bated with a 32phosphate (P)-labelled NF-kB oligonucleotide.
The consensus kB DNA sequence used for the electopho-
retic mobility shift assay (EMSA) was 59AGTTGAGGG-
GACTTTCCCAGGC39 (Promega Corp., Madison, WI, USA).
The oligonucleotide was radiolabelled with [a32P] using T4
polynucleotide kinase (Pharmacia Biotech.). The protein
575FLUTICASONE INHIBITS IkB KINASE-a/b-DEPENDENT PATHWAY
DNA complexes were electrophoresed on a nondenaturing 5%
polyacrylamide gel, then dried under vacuum and exposed at
-80uC with autoradiographic film. In competition studies and
supershift assay, a 100-fold molar excess of unlabelled
oligonucleotide or 1 mg Ab was added to the binding reaction
mixture, prior to the addition of the labelled kB probe.
Identification of the different NF-kB heterodimeric proteins
was carried out by incubating the nuclear extracts with poly-
clonal antibodies against the NF-kB proteins NF-kB1 (p50)
and (p65) RelA (Santa Cruz Biotechnology), prior to the
addition of the labelled kB probe.
Statistical analysis
Results were expressed as mean¡SD. Each data point was
confirmed in triplicate and each cell culture experiment was
performed o3 times. The statistical significance of differences
in cytokine levels was determined by analysis of variance.
Results
Effects of fluticasone propionate on the secretion of
interleukin-6, interleukin-8 and regulated on activation,
T-cell expressed and secreted from cystic fibrosis and
non-cystic fibrosis bronchial epithelial cells
Under resting culture conditions (i.e. over a 4-h period in
the unstimulated state), the spontaneous secretions of IL-8,
IL-6 and RANTES were 3.5-, 8.0- and 10.0-fold higher in CF
bronchial epithelial cells compared to non-CF bronchial
epithelial cells, respectively (fig. 1). Exposure of both CF and
non-CF bronchial epithelial cells to FP (10-9–10-6 M, 4 h)
significantly (pv0.05) reduced the IL-6 and IL-8 secretion
in a dose-dependent manner (fig. 2a–d). A significant reduc-
tion (pv0.05) of RANTES was observed only in non-CF
bronchial epithelial cells with FP at 10-7 M and 10-8 M (fig. 2c
and d). Interestingly, pretreatment with FP (10-8 M) signi-
ficantly (pv0.05) reduced the P. aeruginosa LPS induced IL-8
and IL-6 production in CF and non-CF bronchial cells.
RANTES production was significantly (pv0.01) reduced in
P. aeruginosa LPS stimulated non-CF bronchial epithelial
cells with FP at 10-8 M. There was no significant effect of FP
on unstimulated and P. aeruginosa LPS stimulated RANTES
secretion in CF bronchial epithelial cells (fig. 2c and d).
Exposure of CF and non-CF bronchial epithelial cells to
FP at 10-8 M for a 16-h incubation period resulted in a sig-
nificant decrease of IL-6 and IL-8 production (fig. 3a and b).
In contrast to non-CF bronchial epithelial cells, no significant
decrease of RANTES secretion was observed in CF bronchial
epithelial cells (fig. 3c).
Fluticasone propionate, a potent inhibitor of constitutive
nuclear factor-kB activation in cystic fibrosis bronchial
epithelial cells
Because most pro-inflammatory cytokine genes including
IL-6 and IL-8 contain kB-binding motifs in their promoter
regions, the authors investigated whether the inhibition of
cytokine expression by FP (10-8 M, 16 h) was due to the
reduction of NF-kB activation.
The electrophoretic mobility shift assays (EMSAs) of
nuclear extracts harvested from unstimulated-CF bronchial
epithelial cells demonstrated high constitutive level of activated
NF-kB (fig. 4a, lane 3). In P. aeruginosa LPS stimulated
non-CF bronchial epithelial cells in which the activation of
NF-kB was observed (fig. 4a, lane 1), FP treatment markedly
reduced P. aeruginosa LPS induced NF-kB binding activity
(fig. 4a, lane 2 compared to lane 1). No endogenous NF-kB
binding activity was found in unstimulated-non-CF bron-
chial epithelial cells, as previously reported [24] (data not
shown). Exposure of CF bronchial epithelial cells to FP led
to a strong downregulation of NF-kB (fig. 4a, lane 4). The
specificity of NF-kB DNA-binding was confirmed in com-
petition experiments. Incubation of nuclear extracts from
resting CF bronchial cells with a 100-fold excess of unlabelled
(cold kB) NF-kB oligonucleotide led to a complete inhibition
of binding activity (fig. 4b, lane 1). The components of the
NF-kB DNA-binding protein complex was determined by

































































Fig. 1. – Spontaneous levels of cytokines interleukin (IL)-8, IL-6
and regulated upon activation, normal T-cell expressed and secreted
(RANTES) released by cultured non-cystic fibrosis (non-CF) and
DF508 homozygous cystic fibrosis (CF) bronchial epithelial cells in
the unstimulated (4 h-period) state. Data are presented as mean¡SD
of three separate experiments. ***: pv0.001.
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subunit of NF-kB. As shown in figure 4b, the addition of the
antibodies to p65 caused a supershift (fig. 4b, lane 2).
Fluticasone propionate induces the nuclear factor
inhibitor-kB-a expression
The expression of IkB-a in the absence or presence of
FP (10-8 M, 16 h) was analysed in both CF and non-CF
bronchial epithelial cells. It was shown that an increase in
IkB-a occurs in the cytoplasm of non-CF bronchial epithelial
cells after FP treatment (fig. 5). Compared with untreated CF
bronchial epithelial cells, in which no detectable immuno-
reactivity for IkB-a was observed, FP treatment permitted
the induction and maintenance of IkB-a expression in CF
bronchial epithelial cells (fig. 5a). These results were further
confirmed by Western blot showing that the IkB-a level
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Fig. 2. – Concentration effect of fluticasone propionate (FP) on the release of interleukin (IL)-8 (a, b), IL-6 (c, d) and regulated upon activation,
normal T-cell expressed and secreted (RANTES) (e, f) from cultured human non-cystic fibrosis (non-CF) (a, c and e) versus DF508 homozygous
cystic fibrosis (CF) bronchial epithelial cells incubated for 2 h (b, d, f). Control (Cont.) non-CF and CF bronchial epithelial cells were
maintained either in basal growth medium alone (#) or with Pseudomonas aeruginosa lipopolysaccharide (LPS) added (1.0 mg?mL-1; %). Non-
CF and CF bronchial cells were pretreated with FP for 2 h with ($) or without (&) the addition of P. aeruginosa LPS (1.0 mg?mL-1) for 4 h. Data
are presented as percentage over control CF and non-CF bronchial epithelial cells, respectively. Data represent mean¡SD of three separate experi-
ments each condition carried out in duplicate. *: pv0.05; **: pv0.01 compared with basal growth medium alone or with P. aeruginosa LPS added.
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densitometric analyses raised to 60% of the IkB-a level found in
untreated non-CF bronchial epithelial cells (fig. 5e). These
results, which agree with the EMSA data (fig. 4), indicate
that constitutive NF-kB activation detected in CF bronchial
epithelial cells is reduced with FP treatment via the induction
and the maintenance of cytosolic IkB-a.
Fluticasone propionate reduces the IkB-a/b kinase protein
expressions
To determine whether the level of IkB-a in CF and non-CF
bronchial gland cells before and after FP treatment was
related to the level of IKK-a and IKK-b expressed,
Western blots were performed on cell extracts from CF
and non-CF bronchial gland cells cultured in the absence
or presence of FP (10-8 M, 16 h). In contrast to the level of
IKK-a, an elevated basal level of IKK-b was found in
CF bronchial epithelial cells (a 4.5-fold increase) compared
to that observed in non-CF bronchial epithelial cells. Con-
sistent with the increased level of IkB-a inhibitor after FP
treatment (fig. 6), FP induced a significant reduction of both
the IKK-a and IKK-b kinases in CF and non-CF bronchial
epithelial cells (fig. 6a and b). Interestingly, image analysis
of digitised Western blots of IKK-b level in CF bronchial
epithelial cells after FP treatment revealed a marked decrease
of IKK-b (an 80% reduction) to a level similar to that found
in untreated non-CF bronchial epithelial cells (fig. 6b, lane 4

































































Fig. 3. – Levels of cytokines interleukin (IL)-8, IL-6 and regulated
upon activation, normal T-cell expressed and secreted (RANTES)
released by non-cystic fibrosis (non-CF: %) and DF508 homozygous
cystic fibrosis (CF: u) bronchial epithelial cells after their exposure to
fluticasone propionate (FP) (10-8 M ) for 16 h (z). Data are presented
as mean¡SD of three separate experiments in which each condition
was carried out in duplicate. *: pv0.05; **: pv0.01; ***: pv0.001,
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Fig. 4. – Nuclear factor (NF)-kB binding activity in Pseudomonas
aeruginosa lipopolysacharide (LPS) stimulated non-cystic fibrosis
(non-CF) bronchial cells (a, lane 1) and unstimulated DF508 homo-
zygous cystic fibrosis (CF) bronchial epithelial cells (a, lane 3)
incubated with fluticasone propionate (FP) (10-8 M) for 16 h (a, lanes
2 and 4, respectively). To demonstrate the specificity of binding of the
NF-kB oligonucleotide, a 100-fold M excess of unlabelled NF-kB (b,
lane 5, cold kB) was used to compete with the labelled NF-kB probe.
The addition of antibody to RelA (p65 subunit) component (b, lane 6,
p65) caused a supershift, as indicated. This figure is representative of
three experiments.
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Discussion
The present findings show that FP reduces the IL-6 and
IL-8 production of both unstimulated and P. aeruginosa
LPS stimulated bronchial epithelial cells from non-CF and
CF patients. In CF bronchial epithelial cells, this reduction of
IL-6 and IL-8 production by FP was associated with a strong
reduction of constitutive NF-kB activation, an increased
accumulation of cytosolic IkB-a inhibitor and a reduction
of both IKK-a and IKK-b kinase expression, particularly
marked for IKK-b.
In this study P. aeruginosa LPS was used as an inflam-
matory stimulus in order to increase the pro-inflammatory
cytokine release and to mimic the airway epithelium inflam-





















Fig. 5. – Expression of cytosolic inhibitor of nuclear factor-kB (IkB-a)
protein in non-cystic fibrosis (non-CF: %) and DF508 homozygous
cystic fibrosis (CF: u) bronchial epithelial cells before (a, b) and after
their exposure to fluticasone propionate (FP) (10-8 M) for 16 h (c, d),
as demonstrated by immunofluorescence. Equal amounts of protein
extract from non-CF and DF508 homozygous CF cells treated with
FP or not were analysed for levels of IkB-a by Western blotting using
specific antibodies to IkB-a (e). Densitometric analyses of the data
combined with three similar studies (f), are expressed in arbitrary
units (a.u.). Densitometric results are reported as percentage of IkB-a
levels compared with those obtained from untreated non-CF bron-
chial gland cells (e, lane 1). One representative experiment of three




































Fig. 6. – Expression of inhibitor of nuclear factor-kB kinase (IKK)-a
and IKK-b protein levels in non-cystic fibrosis (non-CF: %) and
DF508 homozygous cystic fibrosis (CF: u) bronchial epithelial cells
after their exposure to 10-8 M fluticasone propionate (FP) for 16 h,
as demonstrated by Western blotting (a and b). Equal amounts of
protein extract from non-CF and DF508 homozygous CF cells treated
with or without FP were analysed for the levels of IKK-a and IKK-b
kinases. Densitometric analyses of the data combined with three
similar studies, are expressed in arbitrary units (a.u.). Densitometric
results are reported as percentage of IKK-a and IKK-b protein levels
compared with those obtained from untreated non-CF bronchial
epithelial cells (a and b, lane 1), respectively. The figure shows
one representative experiment of three independent experiments. **:
pv0.01; ***: pv0.001.
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an in vivo xenograft model of mild inflammation and showed
that FP decreases the LPS-induced IL-8 release. Few studies
have focused on the regulation of IkB proteins in the lungs
after LPS stimulation. MIZGERD et al. [26] have recently
reported that LPS induces a significant loss of IkB-a and
IkB-b in a time-dependent manner, but they did not study
the effect of an anti-inflammatory drug.
In contrast to the decrease of IL-6 and IL-8 after FP in
non-CF and CF bronchial epithelial cells, a weak reduction
of RANTES production was observed in CF bronchial epi-
thelial cells after FP treatment. Some authors have shown
that induction of RANTES expression requires activation
of NF-kB in primary epithelial cells [27], whereas others
have shown that RANTES and IL-8 gene expression are
differently regulated by NF-kB [28]. In the present study, the
lack of FP effect on RANTES expression in CF epithelial
cells suggests that signalling pathways other than NF-kB may
be implicated. DHAWAN et al. [29] recently identified a novel
NF-kB inducing mitogen-activated protein kinase (MAPK)
signaling pathway which is involved in the activation of
IKKs and NF-kB. In the present study, MAPK signaling
might regulate RANTES expression in a NF-kB independent
manner in CF bronchial epithelial cells at resting state and
after FP treatment. Further investigations are necessary to
confirm this hypothesis.
In CF patients, bronchial epithelial cells produce large
amounts of chemokine IL-8, even in the absence of bacterial
infection [6, 24] and lower levels of anti-inflammatory
cytokine IL-10 production [30], which play a central role in
the onset and sustained airway inflammation in CF. Conse-
quently, bronchial epithelial cells represent an important
target of anti-inflammatory molecules and particularly of
inhaled steroids. As previously reported, FP is a steroid with
anti-inflammatory activity characterised by a high affinity for
the steroid-binding site [31]. It has been described as more
potent than other glucocorticoids, such as budenoside and
beclomethasone. at repressing NF-kB activation in alveolar
epithelial cells [32, 33]. In the present study, it was demon-
strated that FP exerts maximal anti-inflammatory effects
with a relevant concentration of FP (10-8 M) in both non-CF
and CF bronchial epithelial cells. Previously the authors had
reported that dexamethasone (DEX) used at higher concen-
trations (10-7–10-5 M) was unable to significantly reduce the
IL-8 production in CF but not in non-CF bronchial epithelial
cells [24]. The reason why FP is more potent than DEX may
be related to the lipophilic nature of FP and to a higher
affinity for its glucocorticoid receptor (GR).
To further identify the potential molecular targets by
which FP exerts its anti-inflammatory effect, the NF-kB/
IkB-a pathway, known to be the major signaling pathway for
the expression of most pro-inflammatory cytokine genes, was
investigated. It was demonstrated, for the first time in the
present study, that within CF bronchial epithelial cells, FP
strongly reduces NF-kB activation which is paralleled with
an increased level of cytosolic IkB-a inhibitor. In addition, it
was also shown that FP decreases the level of both IKK-a
and IKK-b expression, particularly for IKK-b (by a 4.5-fold
reduction) in CF but not in non-CF bronchial epithelial cells.
Further studies will be required to characterise the potential
changes of IKK-a/b kinases and IkB-a at the gene expression
level to improve the understanding of the molecular mechan-
isms (pre- and/or post-transcriptional mechanisms) of FP
action on CF and normal bronchial epithelial cells.
In this study it was shown that the basal level of IKK-b is
excessively elevated in CF bronchial epithelial cells, support-
ing the hypothesis that mechanisms leading to the regulation
of IKK-b expression are altered in CF, a phenomenon that
is probably associated with the sustained inflammatory
process characterising the CF airway disease. The lack of
cytosolic IkB-b inhibitor that had previously been reported by
the authors in CF bronchial epithelial cells in vivo and in vitro
[24] might be mediated in part by the elevated endogenous
level of IKK-b. It is well known that one of the critical
steps in the activation of NF-kB is the phosphorylation of
the IkB-a inhibitor by two IkB kinases, IKK-a and IKK-b,
which leads to its degradation [34]. The mechanism of IKK
activation by pro-inflammatory stimuli is still poorly defined
[35]. The identity of physiological IKK kinases that mediate
its activation in response to different stimuli is the subject of
intense investigation [36]. It has been well recognised that
only in vivo IKK-b and not IKK-a is required for activation
of NF-kB [35]. To date, it is unknown why CF bronchial
epithelial cells exhibit elevated endogenous IKK-b expression
and it remains to be determined how FP reduces IKK-b
expression in CF bronchial epithelial cells. IKK kinases
may be activated by receptor activation at an upstream level,
resulting in IKK phosphorylation. Several potential upstream
IKK kinases could be involved in this activation [35]. Further
investigations are necessary to clarify whether upstream of
IKKs, i.e. NF-kB-inducing kinase and MAP kinases may be
the molecular targets of FP action.
The present data shows, that fluticasone propionate acts
as a negative regulator of nuclear factor-kB activation in
both noncystic fibrosis and cystic fibrosis bronchial epithelial
cells. The data also suggests that elevated endogenous nuclear
factor inhibitor-kB-b kinase expression found in cystic
fibrosis bronchial epithelial cells may be involved in this
regulation. The authors hypothesised that altered nuclear
factor inhibitor-kB-b kinase expression in bronchial epithe-
lium cells may represent a possible mechanism responsible
for aberrant inflammatory responses, characteristic of cystic
fibrosis. Possibly as a result of partially reduced negative
regulation of the nuclear factor-kB activity and the sub-
sequent dysregulation of interleukin-6 and -8 production. In
patients with bronchectasis, it has been shown that inhaled
fluticasone propionate reduced the level of inflammatory
mediators in sputum [37]. In cystic fibrosis patients, flutica-
sone propionate did not induce significant changes in most
of the parameters of pulmonary inflammation (sputum
leukocyte count, myeloperoxydase activity and superoxide
anion release). This may be related to the failure of flutica-
sone propionate to penetrate the viscous mucus lining cystic
fibrosis airways [38]. In vivo, concentrations of inhaled
fluticasone propionate (1 mg?day-1) are estimated to be in
the nanomolar range in human lung tissues forw17 h [39]. In
the present study it was shown that a relevant concentration
of fluticasone propionate (10-8 M for 16 h) reduced the
negative regulator of the nuclear factor-kB activation and
subsequent interleukin-6 and -8 production, by bronchial
epithelial cells of cystic fibrosis patients. Further work is
now required to determine whether the in vitro observations
found in this study can be translated into a clinical mean-
ingful effect in cystic fibrosis patients.
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